Key facts
- Hera-MI’s last known valuation is $11.2M (Jan 2026).
- It has raised $3.3M; the latest was Later Stage VC ($1.5M) in Jan 2026.
- Notable investors include Bpifrance, MassChallenge, Audencia, BNP Paribas, CCI Nantes St-Nazaire — 15 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 15 names
- ·Watchlist + deal alerts for Hera-MI
- ·The full record, as it builds
Funding rounds
No funding rounds for Hera-MI are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Hera-MI
Developer of a patient care system designed to detect breast cancer for radiological cancer diagnosis. The company's system is a patented two and three-dimensional mammography decision support software for breast cancer screening that automatically detects and removes all physiological elements of the breast vessels, connective tissue, mammary gland, muscles, and fat and replaces them with artificial fat, enabling physicians to enhance diagnosis quality and accuracy while reducing radiologists' interpretation time.
- Sector
- Healthcare
- HQ
- Saint-Herblain, France
- Founded
- 2017
- Employees
- 23
- Website
- hera-mi.com/
- Ownership
- Privately Held (backing)
Hera-MI doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Hera-MI shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Hera-MI in its N-PORT filings yet. We sweep new filings monthly.